Drug Trial Radar · NCT06255951
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 12, 2024
Primary completion
May 23, 2024
Study completion Dec 27, 2024
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Studies evaluating the effects of itraconazole or rifampicin on the pharmacokinetics of TY-9591 tablets in healthy subjects
Conditions
- NSCLC
Interventions
ItraconazoleDrug
The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
RifampicinDrug
The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak plasma concentrations (Cmax) of TY-9591 and its metabolites D1 and D2Time frame: through study completion,an average of 6 months
- Area under the concentration-time curve from 0 to the last quantifiable time point after dose administration (AUC0-t)Time frame: through study completion,an average of 6 months
- Area under the concentration-time curve from 0 to infinity (AUC0-inf), as data permitTime frame: through study completion,an average of 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yali Liu
Guangdong, Shantou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.